Clinical Trial Update: KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis [Phase 2, Phase 3]

View source ↗

Summary

Kyverna Therapeutics' KYSA-6 anti-CD19 CAR-T therapy is being evaluated in Phase 2/3 trials for generalized myasthenia gravis, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis
• Myasthenia Gravis

Drugs mentioned

• KYSA-6 (anti-CD19 CAR-T therapy)

Snippet

Sponsor: Kyverna Therapeutics | Conditions: Myasthenia Gravis, Generalized Myasthenia Gravis | Phase 2, Phase 3 | Status: RECRUITING